Early therapy and maximum doses
optimize Lenvatinib benefit
Median PFS
18.3 months
Median PFS
3.6 months
Median PFS
10.1 months
LENVATINIB
(n=261)
Placebo
(n=131
)
96% of eligible patients crossed
over to LENVATINIB (All doses, n=109)
SELECT
Open Label LENVATINIB
Difference in
median PFS:
8.2 months
Median PFS
12.4 months
Difference in
median PFS:
5.9 months
72% of eligible patients crossed
over to LENVATINIB (24mg, n=82)
Schlumberger M. et al.
N Engl J Med
2015
